

# Chapter 116

## Basal Cell Nevus Syndrome

Anthony E. Oro & Jean Y. Tang

### REFERENCES

1. Gorlin RJ: Nevoid basal-cell carcinoma syndrome. *Medicine (Baltimore)* **66**(2):98-113, 1987
2. Gorlin RJ, Goltz RW: Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. *N Engl J Med* **262**:908-912, 1960
3. Howell JB, Caro MR: The basal-cell nevus: Its relationship to multiple cutaneous cancers and associated anomalies of development. *AMA Arch Derm* **79**(1):67-77; discussion 77-80, 1959
4. Farndon PA et al: Analysis of 133 meioses places the genes for nevoid basal cell carcinoma (Gorlin) syndrome and Fanconi anemia group C in a 2.6-cM interval and contributes to the fine map of 9q22.3. *Genomics* **23**(2):486-489, 1994
5. Shanley S et al: Nevoid basal cell carcinoma syndrome: Review of 118 affected individuals. *Am J Med Genet* **50**(3):282-290, 1994
6. Hahn H et al: Mutations of the Human Homolog of *Drosophila* patched in the Nevoid Basal Cell Carcinoma Syndrome. *Cell* **85**:841-851, 1996
7. Johnson RL et al: Human homolog of *patched*, a candidate gene for the basal cell nevus syndrome. *Science* **272**(5268):1668-1671, 1996
8. Ingham PW: Hedgehog signalling. *Curr Biol* **18**(6):R238-R241, 2008
9. Howell JB: Nevoid basal cell carcinoma syndrome. Profile of genetic and environmental factors in oncogenesis. *J Am Acad Dermatol* **11**(1):98-104, 1984
10. Goodrich LV et al: Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science* **277**(5329):1109-1113, 1997
11. Hahn H et al: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med* **4**(5):619-622, 1998
12. Berman DM et al: Medulloblastoma growth inhibition by hedgehog pathway blockade. *Science* **297**(5586):1559-1561, 2002
13. Kimonis VE et al: Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. *Am J Med Genet* **69**(3):299-308, 1997
14. Pruvost-Balland C et al: Etude clinique et recherche de mutations germinales du gene PTCH1 dans le syndrome des hamartomes basocellulaires. *Ann Dermatol Venereol* **113**:117-123, 2006
15. Pastorino L et al: Identification of a SUFU germline mutation in a family with Gorlin syndrome. *Am J Med Genet Part A* **149A**(7):1539-1543, 2009
16. Oro AE: Mammalian variations on a theme: A Smo and Sufu surprise. *Dev Cell* **10**(2):156-158, 2006
17. Taipale J et al: Patched acts catalytically to suppress the activity of Smoothened. *Nature* **418**(6900):892-897, 2002
18. Satir P, Christensen ST: Overview of structure and function of mammalian cilia. *Annu Rev Physiol* **69**:377-400, 2007
19. Rohatgi R, Milenkovic L, Scott MP: Patched1 regulates hedgehog signaling at the primary cilium. *Science* **317**(5836):372-376, 2007
20. Kuwabara PE, Labouesse M: The sterol-sensing domain: Multiple families, a unique role? *Trends Genet* **18**(4):193-201, 2002
21. Reifengerger J et al: Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. *Br J Dermatol* **152**(1):43-51, 2005
22. Ling G et al: PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. *Oncogene* **20**(53):7770-7778, 2001
23. Xie J et al: Activating Smoothened mutations in sporadic basal-cell carcinoma. *Nature* **391**(6662):90-92, 1998
24. Taylor MD et al: Mutations in SUFU predispose to medulloblastoma. *Nat Genet* **31**(3):306-310, 2002
25. Oro AE et al: Basal cell carcinomas in mice overexpressing Sonic Hedgehog. *Science* **276**:817-821, 1997
26. Nilsson M et al: Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing Gli-1. *Proc Natl Acad Sci* **97**(2):3438-3443, 2000
27. Oro AE, Higgins KM: Hair cycle regulation of Hedgehog signal reception. *Dev Biol* **255**(2):238-248, 2003

28. Grachtchouk M et al: Basal cell carcinomas in mice overexpressing Gli2 in skin. *Nat Genet* **24**:216-217, 2000
29. Huntzicker EG et al: Dual degradation signals control Gli protein stability and tumor formation. *Genes Dev* **20**(3):276-281, 2006
30. Epstein EH: Basal cell carcinomas: Attack of the hedgehog. *Nat Rev Cancer* **8**(10):743-754, 2008
31. Aszterbaum M et al: Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. *Nat Med* **5**(11):1285-1291, 1999
32. Sun LS, Li XF, Li TJ: PTCH1 and SMO gene alterations in keratocystic odontogenic tumors. *J Dent Res* **87**(6):575-579, 2008
33. Shear M: The aggressive nature of the odontogenic keratocyst: Is it a benign cystic neoplasm? Part 2. Proliferation and genetic studies. *Oral Oncol* **38**(4):323-331, 2002
34. Lum L, Beachy PA: The hedgehog response network: Sensors, switches, and routers. *Science* **304**(5678):1755-1759, 2004
35. Wicking C et al: Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. *Am J Hum Genet* **60**(1):21-26, 1997
36. Evans DG et al: Complications of the naevoid basal cell carcinoma syndrome: Results of a population based study. *J Med Genet* **30**(6):460-464, 1993
37. Goeteyn M et al: The Bazex-Dupre-Christol syndrome. *Arch Dermatol* **130**(3):337-342, 1994
38. Ashinoff R, Jacobson M, Belsito DV: Rombo syndrome: A second case report and review. *J Am Acad Dermatol* **28**(6):1011-1014, 1993
39. Oley CA, Sharpe H, Chenevix-Trench G: Basal cell carcinomas, coarse sparse hair, and milia. *Am J Med Genet* **43**(5):799-804, 1992
40. Requena L et al: Multiple hereditary infundibulocystic basal cell carcinomas: A genodermatosis different from nevoid basal cell carcinoma syndrome. *Arch Dermatol* **135**(10):1227-1235, 1999
41. Jih DM et al: Familial basaloid follicular hamartoma: Lesional characterization and review of the literature. *Am J Dermatopathol* **25**(2):130-137, 2003
42. Christensen ST et al: Sensory cilia and integration of signal transduction in human health and disease. *Traffic* **8**(2):97-109, 2007
43. Klein RD, Dykas DJ, Bale AE: Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory. *Genet Med* **7**(9):611-619, 2005
44. Kimonis VE et al: Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. *Genet Med* **6**(6):495-502, 2004
45. Ionescu DN, Arida M, Jukic DM: Metastatic basal cell carcinoma: Four case reports, review of literature, and immunohistochemical evaluation. *Arch Pathol Lab Med* **130**(1):45-51, 2006
46. Reymann F: Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. *Dermatologica* **158**(5):368-372, 1979
47. Stockfleth E et al: Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. *Eur J Dermatol* **12**(6):569-572, 2002
48. Wilson BD et al: Photodynamic therapy for the treatment of basal cell carcinoma. *Arch Dermatol* **128**(12):1597-1601, 1992
49. Tjiu J-W et al: Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. *J Invest Dermatology* **129**:1016-1025, 2009
50. Vogel U et al: Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. *Mutat Res* **617**(1-2):138-146, 2007
51. Tang J et al: Basal cell carcinoma chemoprevention with non-steroidal anti-inflammatory drugs in genetically-predisposed PTCH1 +/- humans and mice. *Cancer Prev Res (Phila)* **3**(1):35-24, 2010
52. Bertagnolli MM et al: Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. *Cancer Prev Res* **2**(4):310-321, 2009
53. Williams JA et al: Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions. *Proc Natl Acad Sci U S A.* **100**(8):4616-4621, 2003
54. Von Hoff DD et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* **361**(12):1164-1172, 2009
55. Rudin CM et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med* **361**(12):1173-1178, 2009
56. Yauch RL et al: Smoothed mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. *Science* **326**(5952):572-574, 2009

57. Tremblay MR et al: Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). *J Med Chem* **52**(14):4400-4418, 2009
58. Pazzaglia S et al: High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice. *Oncogene* **21**(49):7580-7584, 2002

